SYD-4228 by Byondis for Follicular Lymphoma: Likelihood of Approval

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

Senolytic agents show promise in mouse model of pelvic organ prolapse

A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), Volume 16, Issue 19

October 22, 2024

Adolescents’ genetic risks tied to psychotic symptoms

Researchers examine the relationships between neuropsychiatric and cognitive polygenic scores, attention-related phenotypes, and psychosis symptoms.

November 1, 2024

Meta Title: “Lonza Group Ltd Patent: Capsule Composition with Pullulan and Setting System

Share this article According to GlobalData’s company profile on Lonza Group, Nanoemulsion cosmetics was a key innovation area identified from patents. Lonza Group‘s grant share

April 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.